Neotigason (Acitretin)

Acitretin, the active ingredient in Neotigason, is a retinoid presented as an oral formulation for oral use. It is employed in the treatment of severe psoriasis, psoriatic keratoderma and other keratinization disorders in adult patients.

GNH USA supplies Neotigason as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neotigason (acitretin) is used in the management of disorders of keratinization and severe psoriasis. - Severe psoriasis: reduces scaling and plaque formation in patients with extensive disease. - Psoriatic keratoderma: improves hyperkeratotic lesions on palms and soles. - Other keratinization disorders: normalizes epidermal differentiation in conditions such as ichthyosis.

Common Side Effects: - Dry skin: increased xerosis and scaling. - Cheilitis: inflammation and cracking of the lips. - Hair loss: temporary alopecia. - Elevated triglycerides: rise in serum lipid levels. - Headache: mild to moderate intensity. - Nausea: gastrointestinal discomfort.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver enzyme elevation. - Severe hyperlipidemia: marked increase in cholesterol or triglycerides. - Bone toxicity: premature epiphyseal closure or osteoporosis. - Pseudotumor cerebri: increased intracranial pressure. - Depression or mood changes. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Neotigason requires careful monitoring due to its potent pharmacologic profile. - Pregnancy contraindication: teratogenic risk mandates effective contraception. - Liver function: baseline and periodic liver enzyme tests are advised. - Lipid monitoring: assess serum triglycerides and cholesterol regularly. - Bone health: avoid use in patients with active bone disorders or severe osteoporosis. - Concomitant vitamin A: avoid additional retinoid sources to prevent toxicity. - Store at ambient temperature: keep in the original pack, protect from moisture.

Acitretin may interact with several medicines, requiring attention to avoid adverse outcomes. Major Interactions (Avoid): - Tetracyclines: increased risk of intracranial hypertension. - Vitamin A supplements: additive teratogenic and toxicity risk. - Other systemic retinoids: cumulative toxicity. - Cholestyramine: reduced acitretin absorption. Moderate Interactions (Monitor Closely): - Oral contraceptives: reduced efficacy, necessitating backup methods. - Statins: potential exacerbation of lipid abnormalities. - Glucocorticoids: heightened risk of hyperlipidemia. - Methotrexate: additive hepatic stress requiring liver function monitoring.